Welcome to the e-CCO Library!

P541: Efficacy, efficiency and aceptability of telemedicine for inflammatory bowel disease patients follow-up care during the COVID-19 pandemic lockdown.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ramos Lopez, L.(1);Reygosa, C.(1);Carrillo-Palau, M.(1);Alonso-Abreu, I.(1);González, Y.(1);de la Barreda, R.(1);Amaral , C.(1);Hernández, A.(1);Benítez-Zafra, F.(1);Hernández-Guerra, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P541: Intestinal failure: a rare but significant outcome of restorative proctocolectomy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Segal J., Oke S., Clark S., Hart A.

Created: Wednesday, 20 February 2019, 10:36 AM
P541: Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Pugliese*1, M. Daperno2, G. Fiorino3, E. Savarino4, E. Mosso5, L. Biancone6, A. Testa7, L. Sarpi8, M. Cappello9, G. Bodini10, F. Caprioli11, S. Festa12, G. Laino13, G. Maconi14, S. Mazzuoli15, G. Mocci16, A. Sartini17, A. D'Amore18, S. Alivernini19, E. Gremese19, A. Armuzzi20

Created: Friday, 22 February 2019, 9:41 AM
P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Kantasiripitak1, B. Verstockt2,3, T. Lobatón2,3,4, D. Thomas1, A. Gils1, S. Vermeire2,3, M. Ferrante2,3, E. Dreesen1

Created: Thursday, 30 January 2020, 10:12 AM
P542: Clinical presentation, disease behavior and management of inflammatory bowel disease at extremes of age
Year: 2021
Source: ECCO'21 Virtual
Authors: Bhangale, N.(1);Desai, D.C.(1);Abraham, P.(1);Gupta, T.(1);Dhoble, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P542: Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Verstockt*1,2, C. Claeys1, G. Van Assche1,2, A. D'Hoore3, A. Wolthuis3, S. Vermeire1,2, M. Ferrante1,2

Created: Friday, 22 February 2019, 9:41 AM
P542: Infliximab salvage therapy in acute severe ulcerative colitis: A systematic review and meta-analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.C. Choy1,2,3*, D. Seah1, D.M. Faleck4, S.C. Shah4, A. Al-Khoury5, Y.-K. An6, G. Radford-Smith6, T. Bessissow5, A.C. Ford7,8, M. Dubinksy4, N. Yeomans2, P. De Cruz1,2

Created: Thursday, 21 February 2019, 9:14 AM
P542: Short term efficacy, safety and thromboembolic risk of tofacitinib in moderate to severe Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cingolani, L.(1);Barberio, B.(1)*;Zelante, A.(2);Ribaldone, D.(3);Testa, G.(3);Bertani, L.(4);Buda, A.(5);Zingone, F.(1);Savarino, E.V.(1);
Created: Friday, 14 July 2023, 11:05 AM
P542: Topical tacrolimus versus systemic biological therapy for refractory ulcerative proctitis: a retrospective cohort study
Year: 2022
Source: ECCO'22
Authors: Crispino, F.(1);Michielan, A.(2);Tieppo, C.(2);Mazza, M.(2);Rogger, T.M.(2);Brinch, D.(1);Cappello, M.(1);Armelao, F.(2);
Created: Friday, 11 February 2022, 3:56 PM
P543 UC remission mucosa displays upregulated inflammatory mediators
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Arkteg1, R. Goll2, M. Dixon Gundersen1, E. Anderssen1, C.G. Fenton1, J. Florholmen2

Created: Thursday, 30 January 2020, 10:12 AM
P543: Higher post-induction infliximab serum trough levels are associated with healing of fistulising perianal Crohn’s disease in children
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. El-Matary1*, T. Walters2, H. Huynh3, J. deBruyn4, D. Mack5, K. Jacobson6, M. Sherlock7, P. Church2, E. Wine3, M. Carroll3, E. Benchimol5, S. Lawrence6, A. Griffiths2

Created: Thursday, 21 February 2019, 9:14 AM
P543: Induction and maintenance of mucosal healing in Crohn's disease with ustekinumab in clinical practice – Results of a nationwide, prospective, multicenter study in Germany (MUCUS)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: BaumgartMD PhD MBA, D.C.(1)*;Stallmach, A.(2);Schubert, A.(3);Howaldt, S.(4);von Arnim, U.(5);Ochsenkühn, T.(6);Stein, J.(7);Lügering, A.(8);Schmidt, D.(9);Schulz, M.(10);Fischer, A.(10);
Created: Friday, 14 July 2023, 11:05 AM
P543: Point-of-care testing in therapeutic drug monitoring of infliximab
Year: 2022
Source: ECCO'22
Authors: Šahinović, I.(1);Orsic Fric, V.(2);Konjik, V.(3);Pavela, J.(4);Borzan, V.(5);Šerić, V.(1);
Created: Friday, 11 February 2022, 3:56 PM
P543: Seven-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Cassieri*1, R. Pica2, E. V. Avallone1, G. Brandimarte3, M. Zippi2, P. Crispino1, D. De Nitto2, P. G. Lecca3, P. Vernia1, P. Paoluzi1, E. S. Corazziari1

Created: Friday, 22 February 2019, 9:41 AM
P543: Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

McCartney S.*1, Lindsay J.2, Russell R.3, Gaya D.3, Shaw I.4, Murray C.5, Finney-Hayward T.6, Sebastian S.7

Created: Wednesday, 20 February 2019, 10:36 AM
P543: The role of social support on psychological distress and health-related quality of life in adults with mild to moderately active Crohn's disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Regev, S.(1);Goren, G.(1);Schwartz, D.(2);Sergienko , R.(3);Friger, M.(4);Nemirovsky , A.(5);Greenberg, D.(6);Monsonego, A.(7);Sarid, O.(1);Slonim-Nevo, V.(1);Odes, S..(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P544 Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Torres-Rodriguez1, F. Cañete1,2, M. Calafat1, R. Sánchez-Aldehuelo3, M. Rivero4,5, M. Iborra2,6, M. González-Vivo7, I. Vera8, L. de Castro9, L. Bujanda2,10,11,12, M. Barreiro-de Acosta13, X. Calvet2,14, J.M. Benítez15,16, M. Llorente17, G. Surís18, L. Arias-García19, M. David20, A. Castaño-García21, F.J. Garcia-Alonso22, L. Rufo23, J.A. Ferrer24, P. Camo25, J.P. Gisbert2,26, J.M. Huguet27, R. Pajares28, V. Morales29, J. Llaó30, A. Rodríguez31, C. Rodríguez32, M. Navarro33, F. Gomollón2,34, M. Carrillo-Palau35, E. Sesé36, P. Almela37, P. Ramírez de la Piscina38, I. Rodríguez-Lago39, M. Papo40, M. Vela41, M. Mañosa1,2, E. Domènech1,2, on behalf of the Eneida-GETECCU investigators

Created: Thursday, 30 January 2020, 10:12 AM
P544: Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease course
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kuehbacher T.*1, Abu Hashem R.1, Langel N.1, Schreiber S.2, Drvarov O.1

Created: Wednesday, 20 February 2019, 10:36 AM
P544: Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE study
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.G. Feagan1*, W.J. Sandborn2, G. D'Haens3, R.K. Pai4, S.B. Hanauer5, D.C. Wolf6, S. Vermeire7, S. Ghosh8, B.G. Levesque9, K. Shan9, R. Aranda9, W.J. Liu9, A. Olson9

Created: Thursday, 21 February 2019, 9:14 AM